Is Compounded Tirzepatide Legal in 2026? What FDA Actually Says

This is a consumer summary of public FDA statements, not legal or medical advice.

Short answer: Compounding tirzepatide isn’t banned outright in 2026, but it’s much narrower than during the shortage. State-licensed 503A pharmacies may compound it for an individual patient with a prescription. They can’t routinely make copies of the approved drug unless a prescriber documents a significant clinical difference for that patient. 503B outsourcing facilities generally can’t compound it from bulk ingredients at all. And compounded tirzepatide is not FDA-approved.

How we got here

• 2022–2024: Tirzepatide and semaglutide were on FDA’s drug shortage list, which allowed broad compounding.
• Late 2024 to early 2025: FDA determined the shortages were resolved. Compounding trade groups sued. A federal court in Texas denied their requests for preliminary injunctions (March 5, 2025 for tirzepatide; April 24, 2025 for semaglutide).
• 2025: FDA’s enforcement grace periods ended, first for 503A pharmacies and then for 503B outsourcing facilities.
• September 2025 to June 2026: FDA began a crackdown on misleading drug advertising, including waves of warning letters to telehealth companies selling compounded GLP-1s.

The rules today (per FDA’s April 1, 2026 update)

503A pharmacies must compound for an individual patient based on a prescription. They can’t compound, “regularly or in inordinate amounts,” drugs that are essentially copies of a commercially available product. FDA treats a compounded drug as essentially a copy when it has the same active ingredient in the same, similar, or easily substitutable strength and the same route, unless a prescriber documents a significant difference for an identified patient. FDA gives the example that semaglutide combined with vitamin B12 may still count as a copy. FDA also said it doesn’t currently intend to act against a compounder that fills four or fewer such prescriptions in a calendar month.

503B outsourcing facilities may compound from bulk ingredients only if the substance is on the 503B bulks list or the drug is on FDA’s shortage list. FDA says tirzepatide and semaglutide are currently on neither.

What FDA is warning telehealth companies about

FDA’s March 3, 2026 announcement of 30 warning letters said the main violations were:

• “claims implying sameness with FDA-approved products”
• “advertising drug products branded with the telehealth firm’s name or trademark without qualification, implying they are the compounder”

So if a provider’s site doesn’t clearly say its compounded tirzepatide isn’t FDA-approved, or describes it as a copy of a brand-name drug, treat that as a red flag. We check every provider we rank against FDA’s warning-letter database.

What this means for you

1. Start with a licensed clinician. FDA recommends compounded drugs only when your needs can’t be met by an approved drug.
2. Expect changes. Rules and enforcement are moving, and a provider’s offerings can change quickly.
3. Choose carefully. Look for a named, state-licensed pharmacy, no FDA warning letters, and honest labeling. See our 9-point checklist.